EGFR and cancer: In this study, we have aimed to describe the sensitivity of cancer cells to a genetically engineered MGL fusion protein selective for EGFR-positive cells (Application for a patent of the Russian Federation No. 2022113614 dated 20 May 2022 “MGL-S3 chimeric enzyme—methionine gamma lyase fused with the S3 domain of the VGF protein from Vaccinia virus, a method for producing MGL-S3 and an antitumor drug based on this enzyme”.